ReGenX Biosciences
A leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.
Launch date
Employees
Market cap
€577m
Enterprise valuation
€391m (Public information from Sep 2024)
Share price
$12.53 RGNX
Rockville Maryland (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 155m | 470m | 113m | 90.2m | 92.2m | 282m | 233m |
% growth | 339 % | 204 % | (76 %) | (20 %) | 2 % | 206 % | (17 %) |
EBITDA | (115m) | 161m | (263m) | (251m) | (200m) | (5.7m) | (153m) |
% EBITDA margin | (74 %) | 34 % | (233 %) | (278 %) | (217 %) | (2 %) | (66 %) |
Profit | (111m) | 128m | (280m) | (263m) | (226m) | (85.7m) | (133m) |
% profit margin | (72 %) | 27 % | (249 %) | (292 %) | (245 %) | (30 %) | (57 %) |
EV / revenue | 7.9x | 2.0x | 5.5x | 5.7x | 5.0x | 1.6x | 2.0x |
EV / EBITDA | -10.6x | 5.9x | -2.4x | -2.0x | -2.3x | -78.3x | -3.1x |
R&D budget | 166m | 181m | 242m | 232m | - | - | - |
R&D % of revenue | 108 % | 39 % | 215 % | 257 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.8m | Grant | ||
$7.7m | Grant | ||
N/A | $7.9m | Early VC | |
$30.0m | Series C | ||
$70.5m | Series D | ||
N/A | N/A | IPO | |
N/A | $87.2m | Post IPO Equity | |
* | N/A | $202m | Post IPO Equity |
N/A | Post IPO Equity | ||
* | N/A | $230m | Post IPO Equity |
* | N/A | $140m | Post IPO Equity |
Total Funding | €108m |
Recent News about ReGenX Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.